- Home
- RDN vs CORT Comparison
RDN vs CORT Comparison
Compare RDN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDN | CORT |
|---|---|---|
| Founded | 1977 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.7B |
| IPO Year | 2008 | 2001 |
Fundamental Metrics
Financial Performance| Metric | RDN | CORT |
|---|---|---|
| Price | $35.12 | $83.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $40.67 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 1.1M | 955.4K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ 5.61 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $1,197,084,000.00 | $761,407,000.00 |
| Revenue This Year | N/A | $26.08 |
| Revenue Next Year | $2.66 | $26.98 |
| P/E Ratio | $38.81 | ★ N/A |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $31.50 | $28.66 |
| 52 Week High | $38.84 | $91.00 |
Technical Indicators
Market Signals| Indicator | RDN | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 86.37 |
| Support Level | $34.39 | $68.20 |
| Resistance Level | $35.85 | $90.00 |
| Average True Range (ATR) | 0.84 | 3.34 |
| MACD | 0.05 | 0.74 |
| Stochastic Oscillator | 80.09 | 95.56 |
Price Performance
Historical ComparisonAbout RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.